Arcus Biosciences, Inc.

RCUSNYSE • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
24.52 USD
↗ 0.24 (0.99%)AT CLOSE (03:59 PM EDT)
24.53
↗ 0.01 (0.04%)
POST MARKET (AS OF 07:30 PM EDT)
Post Market
AS OF 07:30 PM EDT
24.53
↗ 0.01 (0.04%)
🔴Market: CLOSED

RCUS is currently priced at $24.52. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Oct 7, 2026.

Open?$24.23
High?$24.85
Low?$23.90
Prev. Close?$24.28
Volume?1.6M
Avg. Volume?1.5M
VWAP?$24.54
Rel. Volume?1.06x
Bid / Ask
Bid?$23.25 × 100
Ask?$24.98 × 100
Spread?$1.73
Midpoint?$24.12
Valuation & Ratios
Market Cap?3.1B
Shares Out?127.3M
Float?90.6M
Float %?71.1%
P/E Ratio?N/A
P/B Ratio?6.66
EPS?-$3.61
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyBiotech - Drug Development›Immunology & Autoimmune
Employees
601
Market Cap
3.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arcusbio.com
Listed
2018-03-15
Address
3928 POINT EDEN WAY
HAYWARD, CA 94545
Phone: (510) 694-6200
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
6
Momentum?
50
Short Sent.?
40
Piotroski F-Score?0/9Weak
Altman Z-Score?0.57Distress
Confidence?68%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?15.25%High
Short Interest?13.8M
Days to Cover?7.8
Free Float90.6M
Avg Daily Volume1.8M
Settlement Date2026-09-15
Financial Health
Current Ratio?3.82Strong
Quick Ratio?3.82Strong
Cash Ratio?0.76Adequate
Debt/Equity?0.22Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
28
6.66FAIR▾
P/S?
Peers
100
S&P
3
26.42HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.4CHEAP▾
EV/Sales?
Peers
100
S&P
3
26.01HIGH▾
Returns & Efficiency
ROE?
S&P
3
-99.1%WEAK▾
ROA?
S&P
3
-49.8%WEAK▾
Cash Flow & Enterprise
FCF?$-475000000
Enterprise Value?$3.0B
Fundamentals ratios updated end of day
MarketsMoversWatchlist